Plasma Glucose Concentration and Prediction of Future Risk of Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The prevalence of type 2 diabetes has increased in recent decades to epidemic proportions. About 150 million individuals worldwide had type 2 diabetes in 2000, and this number is expected to increase to �300 million by the year 2025 (1). Because of the chronic course of type 2 diabetes and the significant morbidity and mortality associated with the vascular complications of the disease, type 2 diabetes has become not only a serious public health threat, but also a heavy economic burden on the health care system. The total annual cost of diabetes care in the U.S. was estimated to be $175 billion in the
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“Recent clinical trials have reported a reduction in the incidence of type 2 diabetes with lifestyle intervention (3,4) and pharmacotherapy (4,5) in subjects with IGT.”
BackgroundGlucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Self-citationEconomic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
(2006) · The Lancet · doi:10.1016/s0140-6736(06)69420-8 · Cited by 1,706 · cited 1×
“Recent clinical trials have reported a reduction in the incidence of type 2 diabetes with lifestyle intervention (3,4) and pharmacotherapy (4,5) in subjects with IGT.”
BackgroundPathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.013 · Cited by 1,342
Self-citationEconomic costs of diabetes in the U.S. in 2007
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-9017 · Cited by 1,323
Abdul-Ghani, M. A., Tripathy, D., & DeFronzo, R. A. (2006) · Diabetes Care · doi:10.2337/dc05-2179 · Cited by 744
Self-citationPhillips, D. I. W., Clark, P. M., Hales, C. N., & Osmond, C. (1994) · Diabetic Medicine · doi:10.1111/j.1464-5491.1994.tb00273.x · Cited by 631 · cited 1×
“Surrogate measures of -cell function obtained from plasma glucose and insulin concentrations during the OGTT correlate well with -cell function measured with the gold standard hyperglycemic clamp method and have been shown to be good predictors for the future risk of type 2 diabetes (29,30).”
MethodGerstein, H. C., Santaguida, P., Raina, P., Morrison, K. M., Balion, C., Hunt, D., Yazdi, H., & Booker, L. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.05.004 · Cited by 575 · cited 16×
“Subjects care.diabetesjournals.org DIABETES CARE, VOLUME 32, SUPPLEMENT 2, NOVEMBER 2009 S195 with isolated IFG (FPG 100–125 mg/dl and 2-h PG 140 mg/dl) have a 7.5% annual relative risk for future type 2 diabetes compared with NGT subjects (7).”
BackgroundInfluentialGabir, M. M., Hanson, R. L., Dabelea, D., Imperatore, G., Roumain, J., Bennett, P. H., & Knowler, W. C. (2000) · Diabetes Care · doi:10.2337/diacare.23.8.1108 · Cited by 568
Normal fasting plasma glucose levels and type 2 diabetes in young men
Tirosh, A., Shai, I., Tekes-Manova, D., Israeli, E., Pereg, D., Shochat, T., Kochba, I., & Rudich, A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050080 · Cited by 508
Abdul-Ghani, M. A., Jenkinson, C. P., Richardson, D. K., Tripathy, D., & DeFronzo, R. A. (2006) · Diabetes · doi:10.2337/db05-1200 · Cited by 500
Self-citationWhat is the best predictor of future type 2 diabetes
Abdul-Ghani, M. A., Williams, K., DeFronzo, R. A., & Stern, M. (2007) · Diabetes Care · doi:10.2337/dc06-1331 · Cited by 355
Self-citationBeta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study
Gastaldelli, A., Ferrannini, E., Miyazaki, Y., Matsuda, M., & DeFronzo, R. A. (2004) · Diabetologia · doi:10.1007/s00125-003-1263-9 · Cited by 338
Self-citationMeyer, C., Pimenta, W., Woerle, H. J., Van Haeften, T., Szoke, E., Mitrakou, A., & Gerich, J. (2006) · Diabetes Care · doi:10.2337/dc06-0438 · Cited by 308
Weyer, C., Bogardus, C., & Pratley, R. E. (1999) · Diabetes · doi:10.2337/diabetes.48.11.2197 · Cited by 292
Gabir, M. M., Hanson, R. L., Dabelea, D., Imperatore, G., Roumain, J., Bennett, P. H., & Knowler, W. C. (2000) · Diabetes Care · doi:10.2337/diacare.23.8.1113 · Cited by 211
Loss of beta cell function as fasting glucose increases in the non-diabetic range
Godsland, I. F., Jeffs, J. A. R., & Johnston, D. G. (2004) · Diabetologia · doi:10.1007/s00125-004-1454-z · Cited by 131
Abdul-Ghani, M. A., Matsuda, M., Jani, R., Jenkinson, C. P., Coletta, D. K., Kaku, K., & DeFronzo, R. A. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00674.2007 · Cited by 91
Self-citationWho are more insulin resistant, people with IFG or people with IGT?
Wasada, T., Kuroki, H., Katsumori, K., Arii, H., Sato, A., Aoki, K., Jimba, S., & Hanai, G. (2004) · Diabetologia · doi:10.1007/s00125-004-1339-1 · Cited by 55
Cited by
The integrative biology of type 2 diabetes
Roden, M., & Shulman, G. I. (2019) · Nature · doi:10.1038/s41586-019-1797-8 · Cited by 1,167
Adisakwattana, S., Lerdsuwankij, O., Poputtachai, U., Minipun, A., & Suparpprom, C. (2011) · Plant Foods for Human Nutrition · doi:10.1007/s11130-011-0226-4 · Cited by 171
Wagenmakers, A. J. M., Strauss, J. A., Shepherd, S. O., Keske, M. A., & Cocks, M. (2016) · The Journal of Physiology · doi:10.1113/jphysiol.2014.284513 · Cited by 78
Metadata
- Authors
- Abdul-Ghani, M. A., & DeFronzo, R. A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-11-01
- Volume
- 32
- Issue
- suppl_2
- Pages
- S194-S198
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2111191860
- Cited by
- 131
- References
- 22
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.